Orserdu® (elacestrant)
for Breast Cancer

Orserdu (elacestrant) is a targeted therapy used to treat advanced or metastatic estrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation. It is prescribed for postmenopausal women and adult men whose cancer has progressed after endocrine therapy. As a selective estrogen receptor downregulator (SERD), Orserdu blocks estrogen activity in breast tissue, preventing cancer cell growth.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Breast Cancer